Every cholesterol test is really reporting the results of an ongoing showdown happening inside your blood vessels: LDL, trying to deposit cholesterol into artery walls, versus HDL, trying to clean it back out. The LDL/HDL ratio is the simplest way to see who's currently winning that fight.
What the Ratio Is and How to Calculate It
LDL/HDL Ratio = LDL Cholesterol ÷ HDL Cholesterol
If your LDL is 130 mg/dL and your HDL is 50 mg/dL, your ratio is 2.6. Lower numbers mean HDL is holding its own against LDL. Higher numbers mean LDL is pulling ahead, tipping the balance toward artery buildup.
A Fun Bit of History: Meet the Castelli Risk Index
This ratio has an official clinical name that sounds more dramatic than a lab value has any right to: the Castelli Risk Index II. It's named after Dr. William Castelli, the researcher behind decades of landmark Framingham Heart Study findings, including the total cholesterol to HDL ratio we've covered separately, which carries the equally grand title of Castelli Risk Index I.
Castelli and his Framingham colleagues developed both indices while searching for better ways to predict heart disease than any single cholesterol number could offer on its own. Nearly 40 years later, both indices are still in active use in clinical research and cardiovascular risk calculators around the world, a genuinely impressive shelf life for a piece of simple arithmetic.
Why This Ratio Genuinely Matters
The core insight behind Castelli Risk Index II is that LDL and HDL aren't just two separate numbers, they're actively opposing forces. LDL, left unchecked, contributes to plaque formation inside artery walls. HDL works against that process, helping clear cholesterol back out. Looking at either number alone tells you how much of one side showed up. The ratio tells you who's actually winning.
This isn't just a clever way of framing two numbers. Recent research backs up its real-world relevance. A 2026 study following 321 patients with carotid artery narrowing found that Castelli Risk Index II was a meaningful, independent predictor of intraplaque neovascularization, a feature of dangerous, unstable plaques strongly linked to stroke risk. Among the standard lipid measurements and ratios tested, this ratio stood out as a useful early warning sign for plaque instability, not just plaque presence. Other research has found this same ratio outperforms individual LDL or HDL values in specific populations, including people with thyroid conditions that affect cholesterol metabolism, and in older adults with type 2 diabetes, where it has also been linked to cardiovascular and cerebrovascular mortality.
What makes this particularly useful in practice is that it doesn't require anything beyond a routine lipid panel you likely already have. Unlike some of the more advanced markers we've covered elsewhere on this site, there's no extra blood draw, no added cost, and no waiting on a specialty lab. You can calculate it the moment you get your results back.
Proof From Both Directions: Lowering LDL and Raising HDL
Observing that a ratio predicts risk is one kind of evidence. Showing that actually improving the ratio, through two completely different approaches, translates into fewer real-world heart attacks and strokes is a much stronger kind. Two landmark clinical trials did exactly that, approaching the same ratio from opposite directions.
One large trial tested a cholesterol-lowering statin drug in over 6,600 adults with average LDL cholesterol and below-average HDL. The medication worked mainly by lowering LDL. A separate large trial, by contrast, tested a different medication in over 2,500 men with existing coronary heart disease whose LDL was already fairly low but whose HDL was the main problem. This medication worked mainly by raising HDL, with LDL barely moving at all.
| Trial 1: Lowering LDL | Trial 2: Raising HDL | |
|---|---|---|
| Main lipid changed | LDL (down 25%) | HDL (up 6%) |
| Change in the other marker | HDL rose only slightly | LDL essentially unchanged |
| Change in LDL/HDL ratio | Down about 28% | Improved primarily via the HDL side |
| Major coronary events | 37% relative risk reduction | 22% to 24% relative risk reduction |
| Stroke | Not a primary focus | 31% relative risk reduction |
A closer statistical follow-up analysis of the HDL-raising trial made the connection even more direct: for every 5 mg/dL increase in HDL achieved with the medication, coronary events dropped by about 11 percent, while changes in triglycerides or LDL during the trial did not meaningfully predict outcomes on their own. In other words, in this particular trial, the HDL side of the ratio was doing the heavy lifting.
Together, these two trials make a compelling case that the LDL/HDL ratio isn't just a passive number that happens to move alongside real risk. Whether you approach it by bringing LDL down or by bringing HDL up, in the right patient population, improving the balance between the two has been shown to translate into measurably fewer heart attacks and strokes.
What Counts as a Healthy Ratio?
| LDL/HDL Ratio | General Interpretation |
|---|---|
| Below 2.0 | Favorable, HDL is winning the balance |
| 2.0 to 3.5 | Moderate risk |
| Above 3.5 | Elevated risk, LDL is dominating the balance |
As always, these are general population reference points, not a personal verdict, and they're best discussed alongside your full lipid panel with your doctor.
How This Fits Alongside the Other Ratios We've Covered
By now you've likely noticed a pattern across our cholesterol ratio articles: several exist, and each one answers a slightly different question.
| Ratio | What It Really Asks |
|---|---|
| TC/HDL (Castelli Risk Index I) | How much of my total cholesterol burden is protective HDL? |
| LDL/HDL (Castelli Risk Index II) | In the direct fight between "bad" and "good" cholesterol, who's winning? |
| TG/HDL | Am I showing early signs of insulin resistance? |
| ApoB/ApoA-I | Counting actual particles, not just cholesterol content, who's ahead? |
The LDL/HDL ratio's particular strength is its clarity. Unlike TC/HDL, it isn't diluted by the triglyceride-carrying VLDL particles folded into total cholesterol. It's a clean, direct read on the classic bad-versus-good cholesterol relationship, which is exactly why it earned its own dedicated name decades ago and still holds up in current research.
One Honest Caveat
Worth knowing briefly: LDL cholesterol on most standard lab reports is a calculated estimate rather than a direct measurement, and that calculation can become less accurate at high triglycerides or very low LDL levels. Since this ratio relies on that same LDL figure, it inherits this limitation. We cover exactly how this works, and a more accurate alternative formula now used at many labs, in our article on how LDL is calculated rather than measured. This doesn't undermine the ratio's value, it just means very high triglycerides are a good reason to ask your doctor about a more precise LDL calculation before relying heavily on this specific number.
Frequently Asked Questions
Q: Is a very low LDL/HDL ratio always better?
Generally yes, though extremely unusual values in either direction are worth discussing with your doctor, since they can sometimes reflect other underlying factors worth investigating rather than pure cardiovascular protection.
Q: Should I focus on this ratio or the TC/HDL ratio?
Both offer real value and are often reviewed together. The LDL/HDL ratio gives a cleaner, more direct comparison, while TC/HDL captures a broader picture that includes triglyceride-related particles. Your doctor may find one more relevant depending on your specific lipid pattern.
Q: Can improving my ratio actually lower my risk, or is it just a marker?
The lifestyle changes that improve this ratio, regular exercise, reducing saturated fat, maintaining a healthy weight, and not smoking, are independently well established to reduce cardiovascular risk. So while the ratio itself is a marker, the actions that move it in a favorable direction carry real, proven benefit.
Key Takeaway
The LDL/HDL ratio, formally known as the Castelli Risk Index II, distills the ongoing tug-of-war between artery-clogging and artery-clearing cholesterol into one clear number. Born from the same Framingham research that gave us the total cholesterol to HDL ratio, it remains relevant today, with recent research linking it to dangerous, unstable plaque formation and stroke risk. It isn't perfect, since it inherits some of the limitations of calculated LDL values, but it remains one of the more genuinely useful, easy-to-calculate numbers for understanding which side of the cholesterol tug-of-war is currently winning in your body.
References
- Castelli WP, Anderson K, Wilson PWF, Levy D. Lipids and Risk of Coronary Heart Disease: The Framingham Study. Annals of Epidemiology. 1992;2(1-2):23-28. doi.org/10.1016/1047-2797(92)90033-m
- Downs JR, Clearfield M, Weis S, et al. Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS. JAMA. 1998;279(20):1615-1622. doi.org/10.1001/jama.279.20.1615
- Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men With Low Levels of High-Density Lipoprotein Cholesterol. New England Journal of Medicine. 1999;341(6):410-418. doi.org/10.1056/NEJM199908053410604
- Robins SJ, Collins D, Wittes JT, et al. Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events: VA-HIT. JAMA. 2001;285(12):1585-1591. doi.org/10.1001/jama.285.12.1585
- Cui L, Zhou F, Chen Y, et al. The Lipid Ratio Castelli's Risk Index II Is a Novel Biomarker for Intraplaque Neovascularization in Patients With Carotid Stenosis. Lipids in Health and Disease. 2026;25:11. doi.org/10.1186/s12944-025-02821-1